Please assess the completion status of the following clinical trial:

Trial Title: Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with angiomyolipomas and have either Tuberous Sclerosis complex or Lymphangioleiomyomatosis~* Between the gaes of 18 and 65 years~* Competency to voluntarily consent~* Clinically definite diagnosis of tuberous sclerosis or S-LAM~* Adequate contraception~* At least one angiomyolipoma of 1 cm or greater in largest diameter~Exclusion Criteria:~* Use of continuous supplemental oxygen~* Concurrent infection~* Recent surgery~* Ongoing or planned pregnancy~* Lactation~* Use of an investigational drug within the last 30 days of study entrance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).